Research graph
References from First-in-Human, Open-label, Single-Arm Phase I Study of [211At] meta -Astatobenzylguanidine in Patients with Pheochromocytoma or Paraganglioma. Local targets link to admitted publications; unresolved targets remain external evidence.
Update on adrenal tumours in 2017 World Health Organization (WHO) of endocrine tumours
10.1007/s12022-017-9484-5 · 2017 · External reference
Pheochromocytoma and paraganglioma: from epidemiology to clinical findings
10.14744/semb.2020.18794 · 2020 · External reference
Pheochromocytoma and paraganglioma: an Endocrine Society clinical practice guideline
10.1210/jc.2014-1498 · 2014 · External reference
Recent advances in the management of pheochromocytoma and paraganglioma
10.1038/s41440-020-0531-0 · 2020 · External reference
Phaeochromocytoma
10.1016/s0140-6736(05)67139-5 · 2005 · External reference
Treatment of malignant pheochromocytoma/paraganglioma with cyclophosphamide, vincristine, and dacarbazine: recommendation from a 22-year follow-up of 18 patients
10.1002/cncr.23812 · 2008 · External reference
Combination chemotherapy with cyclophosphamide, vincristine, and dacarbazine in patients with malignant pheochromocytoma and paraganglioma
10.1007/s12672-013-0133-2 · 2013 · External reference
Chemotherapy with cyclophosphamide, vincristine and dacarbazine for malignant paraganglioma and pheochromocytoma: systematic review and meta-analysis
10.1111/cen.12542 · 2014 · External reference
Sunitinib for metastatic progressive phaeochromocytomas and paragangliomas: results from FIRSTMAPPP, an academic, multicentre, international, randomised, placebo-controlled, double-blind, phase 2 trial
10.1016/s0140-6736(23)02554-0 · 2024 · External reference
Belzutifan for advanced pheochromocytoma or paraganglioma
10.1056/nejmoa2504964 · 2025 · External reference
Unresolved reference
2018 · External reference
The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine ([131I]MIBG): a comprehensive review of 116 reported patients
10.1007/bf03348026 · 1997 · External reference
Effects and safety of 131I-metaiodobenzylguanidine (MIBG) radiotherapy in malignant neuroendocrine tumors: results from a multicenter observational registry
10.1507/endocrj.ej14-0211 · 2014 · External reference
131I-MIBG therapy for malignant paraganglioma and phaeochromocytoma: systematic review and meta-analysis
10.1111/cen.12341 · 2014 · External reference
Unresolved reference
2018 · External reference
Preclinical evaluation of the acute radiotoxicity of the α-emitting molecular-targeted therapeutic agent 211At-MABG for the treatment of malignant pheochromocytoma in normal mice
10.1016/j.tranon.2019.04.008 · 2019 · External reference
Human dosimetry of free 211At and meta-[211At]astatobenzylguanidine (211At-MABG) estimated using preclinical biodistribution from normal mice
10.1186/s40658-020-00326-7 · 2020 · External reference
Extended single-dose toxicity study of [211At]meta-astatobenzylguanidine in normal mice in preparation for the first-in-human clinical trial of targeted alpha therapy for pheochromocytoma and paraganglioma
10.1007/s12149-025-02065-0 · 2025 · External reference
Meta-[131I]iodobenzylguanidine uptake and meta-[211At]astatobenzylguanidine treatment in human medulloblastoma cell lines
10.1007/bf01054718 · 1995 · External reference
Cytotoxicity of alpha-particle-emitting m-[211At]astatobenzylguanidine on human neuroblastoma cells
1994 · External reference
Antitumor effects of radionuclide treatment using α-emitting meta-211At-astato-benzylguanidine in a PC12 pheochromocytoma model
10.1007/s00259-017-3919-6 · 2018 · External reference
Absorbed dose simulation of meta-211At-astato-benzylguanidine using pharmacokinetics of 131I-MIBG and a novel dose conversion method, RAP
10.1007/s12149-020-01548-6 · 2021 · External reference
Preclinical development of [211At]meta-astatobenzylguanidine ([211At]MABG) as an alpha particle radiopharmaceutical therapy for neuroblastoma
10.1158/1078-0432.ccr-22-0400 · 2022 · External reference
Astatine-211 based radionuclide therapy: current clinical trial landscape
10.3389/fmed.2022.1076210 · 2023 · External reference
Evaluation of pharmacokinetics, safety, and efficacy of [211At]meta-astatobenzylguanidine ([211At]MABG) in patients with pheochromocytoma or paraganglioma (PPGL): a study protocol
10.1371/journal.pone.0303623 · 2024 · External reference
ICH harmonised tripartite guideline. S9 nonclinical evaluation for anticancer pharmaceuticals
2009 · External reference
M3(R2) guidance on nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals
2010 · External reference
Manual on the proper use of meta-[211At]astato-benzylguanidine ([211At]MABG) injections in clinical trials for targeted alpha therapy (1st edition)
10.1007/s12149-022-01765-1 · 2022 · External reference
Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance
10.1136/bmj-2023-076387 · 2023 · External reference
Toxicity and response criteria of the Eastern Cooperative Oncology Group
10.1097/00000421-198212000-00014 · 1982 · External reference
European Association of Nuclear Medicine practice guideline/Society of Nuclear Medicine and Molecular Imaging procedure standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma
10.1007/s00259-019-04398-1 · 2019 · External reference
Common terminology criteria for adverse events (ctcae), version 4.0
2009 · External reference
An open-label, single-arm, multi-center, phase II clinical trial of single-dose [131I]meta-iodobenzylguanidine therapy for patients with refractory pheochromocytoma and paraganglioma
10.1007/s12149-021-01699-0 · 2022 · External reference
Safety and efficacy of multiple-dose versus single-dose MIBG therapy in patients with refractory pheochromocytoma and paraganglioma: a single-center retrospective analysis
10.1007/s12149-024-01928-2 · 2024 · External reference
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
10.1016/j.ejca.2008.10.026 · 2009 · External reference
The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology
10.1093/jnci/85.5.365 · 1993 · External reference
Unresolved reference
2001 · External reference
EQ-5D-5L user guide version 3.0. 2019
External reference
Guidelines for the safe handling of radiopharmaceuticals [in Japanese]
2023 · External reference
Production of 211At and automated radiosynthesis of [211At]MABG via electrophilic astatodesilylation
10.1186/s41181-025-00376-1 · 2025 · External reference
Optimizing MIBG therapy of neuroendocrine tumors: preclinical evidence of dose maximization and synergy
10.1016/j.nucmedbio.2008.04.008 · 2008 · External reference
Transient sialoadenitis: a complication of 131I-metaiodobenzylguanidine therapy
10.1002/pbc.21391 · 2008 · External reference
131I-MIBG therapy in metastatic phaeochromocytoma and paraganglioma
10.1007/s00259-007-0652-6 · 2008 · External reference
Uptake of meta-iodobenzylguanidine in neuroendocrine tumours is mediated by vesicular monoamine transporters
10.1038/sj.bjc.6601276 · 2003 · External reference
Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma
10.1200/jco.2008.21.3496 · 2009 · External reference
Renal excretion of meta-iodobenzylguanidine after therapeutic doses in cancer patients and its relation to dose and creatinine clearance
10.1097/00006231-199509000-00007 · 1995 · External reference
Metabolism of iodine-131 metaiodobenzylguanidine in patients with metastatic pheochromocytoma
1986 · External reference
MIRD pamphlet No. 22 (abridged): radiobiology and dosimetry of α-particle emitters for targeted radionuclide therapy
10.2967/jnumed.108.058651 · 2010 · External reference
Efficacy and safety of high-specific-activity 131I-MIBG therapy in patients with advanced pheochromocytoma or paraganglioma
10.2967/jnumed.118.217463 · 2019 · External reference
